相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of Tyrosine Kinase Inhibitors on the Incidence of Brain Metastasis in Metastatic Renal Cell Carcinoma
Jonathan Verma et al.
CANCER (2011)
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
Astrid A. M. van der Veldt et al.
CLINICAL CANCER RESEARCH (2011)
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2011)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesus Garcia-Donas et al.
LANCET ONCOLOGY (2011)
Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
Thomas E. Hutson
ONCOLOGIST (2011)
Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies
Alain Ravaud
ONCOLOGIST (2011)
Radiologic Assessment of Response to Therapy: Comparison of RECIST Versions 1.1 and 1.0
Hamid Chalian et al.
RADIOGRAPHICS (2011)
Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
Mizuki Nishino et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America
Walter M. Stadler et al.
CANCER (2010)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hypertension and proteinuria: a class-effect of antiangiogenic therapies
Vincent Launay-Vacher et al.
ANTI-CANCER DRUGS (2009)
Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology
Lalitha K. Shankar et al.
CLINICAL CANCER RESEARCH (2009)
Rapid Development of Hypertension by Sorafenib: Toxicity or Target?
Benjamin D. Humphreys et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Trial of Sunitinib Malate plus Interferon-alpha for Patients with Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
CLINICAL GENITOURINARY CANCER (2009)
Imaging techniques to evaluate the response to treatment in oncology: Current standards and perspectives
C. D. Marcus et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Resistance to targeted therapy in renal-cell carcinoma
Brian I. Rini et al.
LANCET ONCOLOGY (2009)
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
Janice P. Dutcher et al.
MEDICAL ONCOLOGY (2009)
Brain metastasis from renal cell carcinoma - Presentation, recurrence, and survival
Brian Shuch et al.
CANCER (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
What is the risk of intracranial bleeding during anti-VEGF therapy?
Craig P. Carden et al.
NEURO-ONCOLOGY (2008)
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Jeanine M. Roodhart et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Mechanisms of adverse effects of anti-VEGF therapy for cancer
T. Kamba et al.
BRITISH JOURNAL OF CANCER (2007)
Renal cell carcinoma guideline
Borje Ljungberg et al.
EUROPEAN UROLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment options in renal cell carcinoma: past, present and future
S. Oudard et al.
ANNALS OF ONCOLOGY (2007)
Imaging vascular physiology to monitor cancer treatment
George R. Laking et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Renal-cell carcinoma
HT Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
MP Upton et al.
JOURNAL OF IMMUNOTHERAPY (2005)
A statistical simulation study finds discordance between WHO criteria and RECIST guideline
M Mazumdar et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control
JP Sheehan et al.
JOURNAL OF NEUROSURGERY (2003)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
NK Janzen et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
